CelLBxHealth plc

As of December 31, 2025, CelLBxHealth plc carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 696.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CelLBxHealth plc's next confirmed earnings release is scheduled for April 29, 2027.

As of December 31, 2025, CelLBxHealth plc has 1.14B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, CelLBxHealth plc maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, CelLBxHealth plc's stock has declined approximately 75.96% over the past 52 weeks. The 50-day moving average sits at 1.02, while the 200-day moving average is 1.16.

As of December 31, 2025, CelLBxHealth plc holds 734.90M in cash and equivalents against 181.70M in total debt, resulting in a net debt position of -734.90M. Total book value stands at 719.60M, with working capital of 661.90M providing operational flexibility.

CelLBxHealth plc's most recent stock split took place on June 6, 2024.